AcelRx post-operative pain treatment meets late-stage study goal

(Reuters) – AcelRx Pharmaceuticals Inc said its experimental drug-device combination to manage post-operative pain met the main goal of a late-stage study on patients who have undergone major open abdominal surgery. The Redwood City, California company’s shares jumped 10 percent to $5.49 after the bell on Monday. The top-line results, reported from a 178-patient study of AcelRx’s Sufentanil NanoTab patient-controlled analgesia (PCA) system, showed that the drug-device combination helped reduce pain significantly compared with a placebo, the company said. …